GlassScriptPhysician profile
Matthew Cotton
NPI 1376914101
$1,991.70
in general payments reported to CMS, 2019-2025
22 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $85.95 · 2023: $258 · 2024: $156 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $456.94 | 2021-2024 | |
| Novo Nordisk INC | $235.12 | 2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $201.93 | 2021-2025 | Jynarque, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.35 | 2025 | Caplyta |
| Abbvie INC. | $176.64 | 2025 | |
| Lilly USA, LLC | $123.94 | 2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $109.93 | 2025 | Symplicity G3 |
| Nuwellis, INC. | $79.31 | 2021 | |
| Akebia Therapeutics INC | $59.95 | 2022-2024 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.40 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $53.56 | 2025 | Breztri, Farxiga, Airsupra |
| Calliditas Therapeutics US INC. | $44.04 | 2023-2024 | Tarpeyo |
| Antares Pharma, INC. | $36.45 | 2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $32.01 | 2025 | Zoryve |
| Travere Therapeutics, INC. | $24.40 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.71 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $19.41 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $18.65 | 2025 | Quviviq |
| Janssen Pharmaceuticals, INC | $17.02 | 2025 | Spravato |
| Amgen INC. | $14.70 | 2024 | Krystexxa |
| Lundbeck LLC | $13.60 | 2025 | Rexulti |
| Vifor Pharma, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cotton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.